Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial
Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial
复制标题
DOI：
10.1007/s12032-022-01754-4
复制
发表时间：
2022-07-19
期刊：
影响因子：
3.4
通讯作者：
Taguchi, Tetsuya
中科院分区：
文献类型：
--
作者：
Kanbayashi, Yuko;Sakaguchi, Koichi;Taguchi, Tetsuya
在以前的研究中，我们发现冷冻疗法和压迫疗法在预防白蛋白结合型紫杉醇诱导的周围神经病变方面具有相当的疗效。然而，即使使用冷冻疗法或加压疗法，也有国家癌症研究所不良事件通用术语标准（CTCAE）4.0版分级>= 2和/或患者神经毒性问卷（PNQ）分级>= D周围神经病变的患者。因此，进行该事后分析以鉴定白蛋白结合型紫杉醇诱导的周围神经病变的预测因子。本事后分析的临床数据为2017年8月至2019年3月在我院门诊化疗中心接受纳米粒白蛋白结合紫杉醇（nab-PTX）化疗的38例乳腺癌患者的数据。假设有76只手的数据，对患者数量进行了分析。与nab-PTX诱导的周围神经病变的发展相关的变量用于回归分析。进行多变量有序逻辑回归分析，以确定nab-PTX诱导的周围神经病变发展的预测因子。显著因素包括吸烟史[比值比（OR）4.64，95%置信区间（CI）1.60-13.5; P = 0.0048]，伴CTCAE评价的神经病变，体重指数（BMI）（OR 1.13，95% CI 1.01-1.26; P = 0.039），伴有通过PNQ（感觉）评估的神经病变和吸烟史（OR 3.80，95% CI 1.40-10.30; P = 0.0087）和年龄（OR 1.06，95% CI 1.01-1.11; P = 0.012），通过PNQ（运动）评价神经病变。总之，吸烟史、BMI和年龄被确定为nab-PTX诱导的周围神经病变发展的重要预测因素。
In a previous study, we showed that cryotherapy and compression therapy have comparable efficacy in preventing nab-paclitaxel-induced peripheral neuropathy. However, even with cryotherapy or compression therapy, there were patients with National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade >= 2 and/or Patient Neurotoxicity Questionnaire (PNQ) grade >= D peripheral neuropathies. Therefore, this post hoc analysis was performed to identify predictors of nab-paclitaxel-induced peripheral neuropathy. The clinical data in this post hoc analysis were the data of 38 breast cancer patients receiving chemotherapy with nanoparticle albumin-bound paclitaxel (nab-PTX) at our outpatient chemotherapy center from August 2017 to March 2019. The number of patients was analyzed assuming that there were data for 76 hands. Variables related to the development of nab-PTX-induced peripheral neuropathy were used for regression analysis. Multivariate-ordered logistic regression analysis was performed to identify predictors for the development of nab-PTX-induced peripheral neuropathy. Significant factors included smoking history [odds ratio (OR) 4.64, 95% confidence interval (CI) 1.60-13.5; P = 0.0048] with neuropathy evaluated by CTCAE, body mass index (BMI) (OR 1.13, 95% CI 1.01-1.26; P = 0.039) with neuropathy evaluated by PNQ (sensory), and smoking history (OR 3.80, 95% CI 1.40-10.30; P = 0.0087) and age (OR 1.06, 95% CI 1.01-1.11; P = 0.012) with neuropathy evaluated by PNQ (motor). In conclusion, smoking history, BMI and age were identified as significant predictors of the development of nab-PTX-induced-peripheral neuropathy.